Navigation Links
Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients
Date:3/19/2008

nding the current product label into adult AML. Preliminary data has been accepted for presentation at ASCO this spring and a supplemental new drug application (sNDA) for clofarabine is expected to be filed in the second half of this year. It is possible that data from this study also could be considered for part of a new filing with EMEA.

Evoltra is currently indicated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients who have relapsed or are refractory to at least two prior regimens. The withdrawal of the European application of Evoltra in adult AML has no consequences for patients enrolled in current clinical trials or compassionate use programs.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 10,000 employees in locations spanning the globe and 2007 revenues of $3.8 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

This press release contains forward-looking statements, including the expected results of the data generated from clofarabine clinical trials, the presentation and use of this data to support regulatory filings, and t
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , ... July 01, 2015 , ... Apex Therapeutics announced ... International Convention in Philadelphia, PA. , The presentation took place on Tuesday, ... the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... 2015 R-Japan Co.,Ltd. obtained the license of cell ... Medicine from the Ministry of Health, Labour and Welfare Kinki ... The fact that R- Japan ... from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, ... provide stem cell manufacturing service to medical institutions. As of ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... a webinar to provide advanced scientific research into new classes of Nanoscale Graphene-based ... energy. Touted as 'the wonder material of the 21st Century' by the ...
(Date:6/30/2015)... Americord Registry, one of the fastest growing cord blood banks ... at Kirkland & Ellis LLP, as the newest member of ...   "We are thrilled about Andrew Horne,s ... , CEO of Americord. "He brings a wealth of knowledge ... growth and vision." Andrew Horne is ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4Americord Registry Announces Andrew Horne as Advisory Board Member 2
... week, I gave you my predictions for the coming year ... few of these predictions come true, 2007 is going to ... Lamis , founder of Singularity University , a community ... worried. Second Life becomes a credible next-generation platform ...
... Wis. - To find out whether radio frequency ... blood banking process, the RFID Lab at the ... banks and multiple vendor partners on what is being called ... at RFID's potential role from donation to transfusion, involves the ...
... Inc. , has announced it will price a forthcoming ... at $3.75 per share. , ,Proceeds from the ... 2006, will be used to support research and development ... and intellectual property protection. The Madison-based company, which has ...
Cached Biology Technology:Reader predictions would make 2007 quite a year 2Reader predictions would make 2007 quite a year 3Reader predictions would make 2007 quite a year 4Reader predictions would make 2007 quite a year 5RFID pilot project aims to improve blood banks 2RFID pilot project aims to improve blood banks 3
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)...   MedNet Solutions , an innovative SaaS-based ... of clinical research, is pleased to announce that ... company,s intuitive, flexible and affordable cloud-based eClinical technology ... Award by the American Business Awards (SM) ... The American Business Awards are considered the nation,s ...
(Date:6/23/2015)... , June 23, 2015  Crossmatch™, ... and authentication solutions, today announced enhanced functionality of ... authentication solution.  The enhancements build on the ... the DigitalPersona Altus platform and provide expanded ... In today,s environment of increasing ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2Crossmatch Releases Enhanced DigitalPersona Altus Advanced Authentication Functionality 2
... The way the liver renews itself may be simpler than ... the April 13 issue of The Journal of Biological Chemistry, ... regenerating livers that could significantly affect the way physicians make ... hepatitis, or cancer. , "The human liver is one ...
... many to be creepy-crawly, are giving new meaning to ... whip spiders, or amblypygids, mothers caress their young with ... maturity, and all mix in social groups. This is ... aggressive and anti-social, according to a Cornell researcher. ...
... scientists for a dog snapper is actually a new ... of the South Atlantic Ocean. , The international science ... new snapper species that belongs to the Lutjanidae family, ... Kenyon Lindeman of Environmental Defense. The study published in ...
Cached Biology News:Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3A rarity among arachnids, whip spiders have a sociable family life 2A rarity among arachnids, whip spiders have a sociable family life 3New species of snapper discovered in Brazil 2
... is the most thoroughly characterized enzyme available ... its overall utility and efficacy. , Its ... PCR applications. , It is QC ... AmpliTaq DNA Polymerase is a 94 kDa ...
Taq DNA Polymerase (T. aquaticus), 4 x 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying En...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Aspergillus (IgG) Ab EIA Sample Size: 100 l...
Biology Products: